Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9506465 | 1.00 | CTSK (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL9507143 | 1.00 | CTSK (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL24575146 | 0.86 | CTSK (0.55) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL4751952 | 0.81 | CTSK (0.59) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL28681860 | 0.81 | CTSK (0.59) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL3048922 | 0.81 | CTSK (0.59) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL59323 | 0.80 | CTSK (0.61) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL256794 | 0.80 | CTSK (0.61) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL29674710 | 0.80 | CTSK (0.61) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL467994 | 0.80 | CTSK (0.61) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190125888-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2019-05-02 | — | — | US | disclosed |
| US-20170283446-A1 | SOLUBLE C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283446-A1 | SOLUBLE C5aR ANTAGONISTS | C5AR1, C3AR1, C5AR2 | CTSK 981/4885CTSS 753/4885CA2 3527/4885 |
| US-20190125888-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR4, SSTR5, SSTR1 | CTSK 1186/4885CTSS 796/4885CA2 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.